Want to see KPTI full AI Analyst Report?
KPTI Stock Chart & Stats
$1.92
-$0.32(-4.32%)
At close: 4:00 PM EDT
$1.92
-$0.32(-4.32%)
Day’s Range― - ―
52-Week Range$1.24 - $10.99
Previous Close$7.09
Volume527.47K
Average Volume (3M)1.27M
Market Cap
$39.24M
Enterprise Value$473.81
Total Cash (Recent Filing)$65.11M
Total Debt (Recent Filing)$215.88M
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Oct 29, 2026EPS Estimate
-0.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-22.32
Shares Outstanding22,681,460
10 Day Avg. Volume1,777,292
30 Day Avg. Volume1,269,742
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.27
Price to Sales (P/S)0.55
P/FCF Ratio-1.07
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.54Price Target Upside240.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-4.91
Revenue Forecast (FY)$136.60M
Bulls Say, Bears Say
Bulls Say
Myelofibrosis Regulatory ProgressThe submitted sNDA creates a defined regulatory pathway for expanding selinexor into myelofibrosis, while the Priority Review request could accelerate the decision. If accepted and approved, the indication would broaden the commercial base and provide a durable growth opportunity beyond current uses.
Strong Phase III Clinical EvidenceStatistically significant spleen-volume reduction, sustained responses, and a favorable overall-survival signal strengthen the clinical case for the selinexor combination. This evidence supports regulatory engagement, potential adoption in myelofibrosis, and a more valuable long-term product platform if confirmatory data validate benefit.
Established Commercial PlatformExisting XPOVIO sales, patient-support capabilities, and coverage across community and academic settings provide a foundation for continued commercialization. Stable product revenue and reaffirmed guidance indicate operating infrastructure that could also support a faster launch if the myelofibrosis indication is approved.
Bears Say
Severe Liquidity And Default RiskThe missed debt payment and temporary forbearance indicate immediate financing pressure rather than a normal capital structure. Management says liquidity may last only through October 15, 2026, so failure to secure capital or strategic support could disrupt operations, limit investment, and threaten business continuity.
Negative Equity And Ongoing Cash BurnDeeply negative equity, substantial debt relative to assets, and continuing free-cash-flow losses leave the company dependent on external funding. Although cash burn has improved, the business is not self-funding, reducing flexibility to absorb setbacks or finance development from internal resources.
Limited Profitability And Pipeline SetbackFlat-to-declining revenue and very large losses show that the existing commercial base does not yet cover operating costs. The failed endometrial-cancer Phase III endpoint also led to sharply reduced investment, narrowing pipeline diversification and increasing reliance on the myelofibrosis program.
Karyopharm Therapeutics News
KPTI FAQ
What was Karyopharm Therapeutics’s price range in the past 12 months?
Karyopharm Therapeutics lowest stock price was $1.24 and its highest was $10.99 in the past 12 months.
What is Karyopharm Therapeutics’s market cap?
Karyopharm Therapeutics’s market cap is $39.24M.
When is Karyopharm Therapeutics’s upcoming earnings report date?
Karyopharm Therapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 33 days.
How were Karyopharm Therapeutics’s earnings last quarter?
Karyopharm Therapeutics released its earnings results on Aug 13, 2026. The company reported -$2.32 earnings per share for the quarter, missing the consensus estimate of -$1.372 by -$0.948.
Is Karyopharm Therapeutics overvalued?
According to Wall Street analysts Karyopharm Therapeutics’s price is currently Undervalued.
Does Karyopharm Therapeutics pay dividends?
Karyopharm Therapeutics does not currently pay dividends.
What is Karyopharm Therapeutics’s EPS estimate?
Karyopharm Therapeutics’s EPS estimate is -0.95.
How many shares outstanding does Karyopharm Therapeutics have?
Karyopharm Therapeutics has 22,681,460 shares outstanding.
What happened to Karyopharm Therapeutics’s price movement after its last earnings report?
Karyopharm Therapeutics reported an EPS of -$2.32 in its last earnings report, missing expectations of -$1.372. Following the earnings report the stock price went down -1.97%.
Which hedge fund is a major shareholder of Karyopharm Therapeutics?
Currently, no hedge funds are holding shares in KPTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Karyopharm Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.54 (240.42% Upside)
$6.54 (240.42% Upside)
Blogger Sentiment
Neutral
KPTI Sentiment 50%
Sector Average 63%
Sector Average 63%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.3%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.14%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Karyopharm Therapeutics
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
KPTI Company Deck
KPTI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed materially positive clinical and regulatory progress—most notably compelling Phase III SENTRY data, constructive FDA interactions around SVR35 as a surrogate endpoint, an on-track sNDA submission, publication/presentation of results, and steady XPOVIO commercial performance—positioning the company for a potential accelerated approval and a sizeable myelofibrosis market opportunity. Offsetting these positives are significant near-term financial risks: a missed endometrial cancer Phase III endpoint that reduced pipeline diversification, a widened reported net loss driven by non-cash financing impacts, limited cash runway (liquidity into September 2026) and an upcoming $15.8M loan payment that could trigger a covenant default without new financing or waivers. Regulatory timing uncertainty (need for long-term OS confirmatory data) and transitional expense pressures add further near-term risk. Overall, the call balanced strong clinical momentum and commercial readiness against pronounced short-term financial and execution risks.View all KPTI earnings summariesKPTI Stock 12 Month Forecast
Average Price Target
$6.54
▲(240.42% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
―
Lantern Pharma
―
Century Therapeutics
―
Medicus Pharma Ltd
―
Ownership Overview
3.66% Insiders
18.50% Mutual Funds
54.39% Other Institutional Investors
13.81% Public Companies and
Individual Investors